{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:31:57Z","timestamp":1777905117917,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.clinthera.2020.08.015","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T09:08:10Z","timestamp":1601024890000},"page":"2148-2158.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cost-effectiveness of Capecitabine\u00a0+ Irinotecan Versus Leucovorin\u00a0+ Fluorouracil\u00a0+ Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China"],"prefix":"10.1016","volume":"42","author":[{"given":"Qiuji","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiting","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.08.015_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2020.08.015_bib2","first-page":"653","article-title":"Predictors of survival in stage IV metastatic colorectal cancer","volume":"30","author":"Zacharakis","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clinthera.2020.08.015_bib3","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.3748\/wjg.v13.i28.3806","article-title":"Metastatic colorectal cancer-past, progress and future","volume":"13","author":"Field","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2020.08.015_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.08.015_bib5","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0959-8049(99)00150-1","article-title":"CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer","volume":"35","author":"Andre","year":"1999","journal-title":"GERCOR Eur J Cancer"},{"key":"10.1016\/j.clinthera.2020.08.015_bib6","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study","volume":"25","author":"Fuchs","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.08.015_bib7","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer","volume":"343","author":"Saltz","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.015_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.015_bib9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S1470-2045(18)30140-2","volume":"19","author":"Xu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2020.08.015_bib10","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.clinthera.2020.08.015_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.bjc.6605114","article-title":"Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials","volume":"101","author":"Shiroiwa","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2020.08.015_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/ajco.12044","article-title":"Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia","volume":"9","author":"Tran","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.08.015_bib13","doi-asserted-by":"crossref","first-page":"17976","DOI":"10.3748\/wjg.v20.i47.17976","article-title":"Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials","volume":"20","author":"Wen","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2020.08.015_bib14","first-page":"125","article-title":"Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients","volume":"22","author":"De Portu","year":"2010","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.clinthera.2020.08.015_bib15","doi-asserted-by":"crossref","first-page":"e968","DOI":"10.1016\/S2214-109X(19)30201-3","article-title":"Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model","volume":"7","author":"Tang","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.clinthera.2020.08.015_bib16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0140-6736(01)06107-4","article-title":"Introduction to health economics for physicians","volume":"358","author":"Meltzer","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.08.015_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.21147\/j.issn.1000-9604.2019.01.07","article-title":"Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)","volume":"31","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.clinthera.2020.08.015_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2019.08.028","article-title":"Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores","volume":"136","author":"Zhou","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clinthera.2020.08.015_bib20","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"1997"},{"key":"10.1016\/j.clinthera.2020.08.015_bib21","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s11136-009-9513-z","article-title":"Health utility scores of colorectal cancer based on societal preference in Japan","volume":"18","author":"Shiroiwa","year":"2009","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2020.08.015_bib22","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2014.58.4904","article-title":"First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis","volume":"33","author":"Goldstein","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.08.015_bib23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2006.09.0738","article-title":"Interpreting the economic literature in oncology","volume":"25","author":"Grusenmeyer","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.08.015_bib24","article-title":"Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource\u2013limited setting","volume":"7","author":"Wu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2020.08.015_bib25","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1200\/JCO.2015.61.9569","article-title":"Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer","volume":"33","author":"Goldstein","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.08.015_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1478-7547-1-8","article-title":"Generalized cost-effectiveness analysis for national-level priority-setting in the health sector","volume":"1","author":"Hutubessy","year":"2003","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.clinthera.2020.08.015_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O","article-title":"Development of WHO guidelines on generalized cost-effectiveness analysis","volume":"9","author":"Murray","year":"2000","journal-title":"Health Econ"},{"key":"10.1016\/j.clinthera.2020.08.015_bib28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","article-title":"Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?","volume":"7","author":"Eichler","year":"2004","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2020.08.015_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/hec.793","article-title":"Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale","volume":"13","author":"Elbasha","year":"2004","journal-title":"Health Econ"},{"key":"10.1016\/j.clinthera.2020.08.015_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS","volume":"29","author":"Yoshino","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2020.08.015_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/egh.10.90","article-title":"XELOX in colorectal cancer: a convenient option for the future?","volume":"5","author":"Lindsay","year":"2011","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2020.08.015_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/annonc\/mdj023","article-title":"A\u00a0randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil\/leucovorin regimens in patients with advanced colorectal cancer","volume":"17","author":"Twelves","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2020.08.015_bib33","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/1471-2407-11-288","article-title":"Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement","volume":"11","author":"Tse","year":"2011","journal-title":"BMC Cancer"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820304215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820304215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:56Z","timestamp":1758963176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820304215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0149291820304215"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.08.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of Capecitabine\u00a0+ Irinotecan Versus Leucovorin\u00a0+ Fluorouracil\u00a0+ Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}